Bergen, Norway, 31 May 2019 – BerGenBio ASA (OSE:BGBIO), will share its latest updates and data on an investor call on 4 June 2019, during the annual American Society of Clinical Oncology (ASCO) meeting. BerGenBio’s senior management team will be hosting the call at 15:30 CET.
Dial-in details are:
· Standard International Dial-In: +44 (0) 2071 928000
· United States Dial-In: 16315107495
· Participant Code: 4352428
The call will focus on two peer reviewed abstracts on Phase II clinical data with bemcentinib in the treatment of Non-Small Cell Lung Cancer and Acute Myeloid